|
|
Clinical effect of Edaravone combined with Vinpocetine Injection in the treatment of acute cerebral infarction |
YANG Yu-sheng1 LIU Zhen-peng1 HUANG Yao-zhong2 |
1.The Seventh Department of Internal Medicine,Lufeng People′s Hospital,Shanwei City,Guangdong Province,Lufeng 516500,China;
2.Department of Neurology,Citic Huizhou Hospital,Guangdong Province,Huizhou 516006,China |
|
|
Abstract Objective To explore the clinical effect of Edaravone combined with Vinpocetine Injection in the treatment of acute cerebral infarction(ACI).Methods Seventy patients with ACI treated in Lufeng People′s Hospital from January 2018 to March 2019 were selected as research subjects.They were divided into the control group and the observation group according to the random number table method,with 35 cases in each group.Patients in the control group were treated with Edaravone,and patients in the observation group were treated with Vinpocetine Injection on the basis of the control group.The clinical efficacy,incidence of adverse reactions,and neurological function(national institute of health stroke scale[NIHSS])score,inflammatory factors(tumor necrosis factor-α[TNF-α),and matrix metalloproteinase-3[MMP-3])and oxidative stress(superoxide dismutase[SOD],malondialdehyde[MDA])levels before and after treatmentwere compared between the two groups.Results The total effective rate of treatment in the observation group was 97.14%,which was higher than 77.14%in the control group,and the difference was statistically significant(P<0.05).The NIHSS score of patients in the observation group after treatment was(9.61±1.80)points,which was lower than that in the control group of(12.36±2.19)points,and the difference was statistically significant(P<0.05).The levels of TNF-αand MMP-3 in the observation group after treatmentwere(72.31±15.22)and(2.63±0.62)μg/L,which were lower than those in the control group for(95.24±18.45)and(4.11±0.89)μg/L,the differences were statistically significant(P<0.05).The SOD level in the observation group after treatmentwas(39.62±3.50)IU/ml,which was higher than that in the control group for(32.81±2.17)IU/ml,and the MDA level was(9.95±1.16)μmol/L,which was lower than that in the control group for(13.34±1.11)μmol/L,the differences were statistically significant(P<0.05).No serious adverse reactions occurred in both groups.Conclusion The combination of Edaravone and Vinpocetine Injection can effectively improve the neurological function of patients with ACI,enhance the treatment effect,reduce the level of inflammatory factors,regulate the oxidative stress response and speed up the recovery of patients.
|
|
|
|
|
[1] |
梁炳松,李育英,张岐平,等.急性脑梗死患者病情进展的影响因素[J].广西医学,2018,40(6):615-618.
|
[2] |
赖苹,何彦玲,杨超.急性脑梗死患者颈动脉粥样硬化及血流动力学参数变化[J].海南医学,2018,29(5):669-671.
|
[3] |
陈庆友,张艳蕉,于熙莹.丁苯酞联合依达拉奉治疗急性脑梗死的临床研究[J].中国临床药理学杂志,2016,32(16):1453-1455.
|
[4] |
余敏燕.尤瑞克林联合依达拉奉对ACI的临床疗效及神经功能的影响[J].西南国防医药,2018,28(3):239-241.
|
[5] |
闫纪琳.长春西汀联合依达拉奉治疗脑梗死后血管性认知障碍120例[J].神经损伤与功能重建,2016,11(4):342-343.
|
[6] |
曹兵,丁奇,刘熙鹏,等.大株红景天注射液联合长春西汀注射液治疗急性大面积脑梗死的临床观察[J].中国药房,2017,28(32):69-71.
|
[7] |
中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.
|
[8] |
梁鹏飞,雷青梅.急性脑梗死患者血清同型半胱氨酸和组织基质金属蛋白酶抑制剂水平检测及临床意义[J].中国药物与临床,2018,18(6):184-185.
|
[9] |
何志红.参附注射液辅助治疗急性心衰的效果及对TIMP-1、MMP-3的影响[J].中国医药导报,2016,13(31):105-108.
|
[10] |
张作念,王志晔,顾伟,等.急性脑梗死患者血清炎症因子与颈动脉粥样硬化斑块性质关系的临床研究[J].重庆医学,2016,45(10):1375-1377.
|
[11] |
程文静,张晓雪,张磊.葛根素联合依达拉奉对急性脑梗死患者炎症因子的影响[J].中国中医急症,2016,25(2):245-247.
|
[12] |
季志刚,王颖建,周雪东.依达拉奉对颅脑损伤手术患者氧自由基清除能力及脑血流参数的影响[J].西部医学,2018,30(6):61-64.
|
[13] |
张璐璐.静脉溶栓对急性脑梗死患者氧化应激反应及神经功能的影响[J].河北医学,2016,48(8):1262-1265.
|
[14] |
龙其泰.依达拉奉与长春西汀联合乌司他丁治疗急性脑出血的疗效对比分析[J].山西医药杂志,2016,45(1):6-9.
|
[15] |
范红娟.长春西汀联合依达拉奉治疗急性脑梗死疗效及对血浆炎性因子的影响[J].现代中西医结合杂志,2017,26(19):2126-2128.
|
|
|
|